Movatterモバイル変換


[0]ホーム

URL:


Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Wiley full text link Wiley Free PMC article
Full text links

Actions

.2019 Oct;42(10):1351-1357.
doi: 10.1111/jfd.13057. Epub 2019 Jul 15.

Further evaluation of the efficacy of emamectin benzoate for treating Pseudocapillaria tomentosa (Dujardin 1843) in zebrafish Danio rerio (Hamilton 1822)

Affiliations

Further evaluation of the efficacy of emamectin benzoate for treating Pseudocapillaria tomentosa (Dujardin 1843) in zebrafish Danio rerio (Hamilton 1822)

Michael L Kent et al. J Fish Dis.2019 Oct.

Abstract

Pseudocapillaria tomentosa is a pathogenic nematode parasite, causing emaciation and severe inflammatory lesions in the intestines in zebrafish Danio rerio (Hamilton 1822). Emamectin benzoate is commercially available analogue of ivermectin used for treating salmon for sea lice, under the brand name SLICE® , and we have used this for treating zebrafish with the P. tomentosa. Here, SLICE® , 0.2 per cent active emamectin benzoate, was used for oral treatments at 0.35 mg emamectin benzoate/kg fish/day for 14 days starting at 7 days post-exposure (dpe). Another experiment entailed initiating treatment during clinical disease (starting at 28 dpe). Early treatment was very effective, but delaying treatment was less so, presumably due to inappetence in clinically affected fish. We evaluated emamectin benzoate delivered in water, using Lice-Solve™ (mectinsol; 1.4% active emamectin benzoate) in two experiments. Application of four 24-hr treatments, space over 7 days was initiated at 28 dpe at either 0.168 or 0.56 mg emamectin benzoate/L/bath, and both treatments completely eradicated infections. This was 3 or 10 times manufacture's recommended dose, but was not associated with clinical or histological side effects.

Keywords: Pseudocapillaria tomentosa; emamectin benzoate; zebrafish Danio rerio.

© 2019 John Wiley & Sons Ltd.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors declare no conflict of interest.

References

    1. Barton CL, Johnson EW, & Tanguay RL (2016). Facility design and health management program at the Sinnhuber Aquatic Research Laboratory. Zebrafish,13 (Suppl 1), 39–43.DOI.org/10.1089/zeb.2015.1232 - DOI - PMC - PubMed
    1. Bozdogon H (1987). Model selection and Akaike’s Information Criterion (AIC): The general theory and its analytical extensions. Psychometrika, 52, 345–370.
    1. Campbell WC (2012). History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents. Current Pharmaceutical Biotechnology 13, 853–865. DOI: 10.2174/138920112800399095 - DOI - PubMed
    1. Collymore C, Watral V, White JR, Colvin ME, Rasmussen S, Tolwani RJ, & Kent ML (2014). Tolerance and efficacy of emamectin benzoate and ivermectin for the treatment ofPseudocapillaria tomentosa in laboratory zebrafish (Danio rerio). Zebrafish, 11, 490–497. doi: 10.1089/zeb.2014.1021 - DOI - PMC - PubMed
    1. Davies IM, & Rodger GK (2000). A review of the use of ivermecti as a treatment for sea lice(Lepeophtheirus salmonis (KrØyer) andCaligus elongates Nordmann) infestation in farmed Atlantic salmon (Salmo salar). Aquaculture Research, 21, 869–883. 10.1046/j.1365-2109.2000.00510.x| - DOI

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full text links
Wiley full text link Wiley Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.


[8]ページ先頭

©2009-2026 Movatter.jp